Low levels of MCL-1 were correlated with sensitivity to venetoclax and navitoclax [24], whereas the exogenous expression of MCL-1, including in primary ALL cells, reduced the sensitivity of the cells to navitoclax and rendered venetoclax ineffective [14]. Here, MCL1 is linked to acute lymphoblastic leukemia.